Joel Greenblatt's RMD Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 86,133 shares of ResMed Inc. (RMD) worth $20.75 M, representing 0.08% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in RMD, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2014, adding 295,129 shares. Largest reduction occurred in Q2 2014, reducing 511,695 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's ResMed (RMD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ResMed (RMD) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +35,428 | Add 69.87% | 86,133 | $240.87 |
| Q3 2025 | +39,035 | Add 334.49% | 50,705 | $273.73 |
| Q2 2025 | -7,275 | Reduce 38.40% | 11,670 | $258.00 |
| Q1 2025 | -6,935 | Reduce 26.80% | 18,945 | $223.85 |
| Q4 2024 | -20,563 | Reduce 44.28% | 25,880 | $228.69 |
| Q3 2024 | +2,242 | Add 5.07% | 46,443 | $244.12 |
| Q2 2024 | +18,851 | Add 74.36% | 44,201 | $191.42 |
| Q1 2024 | +13,971 | Add 122.78% | 25,350 | $198.03 |
| Q4 2023 | -2,396 | Reduce 17.39% | 11,379 | $172.02 |
| Q3 2023 | +10,196 | Add 284.88% | 13,775 | $147.87 |
| Q2 2023 | +3,579 | New Buy | 3,579 | $218.50 |
| Q1 2023 | -1,005 | Sold Out | 0 | $0.00 |
| Q4 2022 | +12 | Add 1.21% | 1,005 | $208.13 |
| Q3 2022 | -52 | Reduce 4.98% | 993 | $218.53 |
| Q2 2022 | -44 | Reduce 4.04% | 1,045 | $209.57 |
| Q1 2022 | -5,473 | Reduce 83.40% | 1,089 | $242.42 |
| Q4 2021 | +6,562 | New Buy | 6,562 | $260.44 |
| Q1 2021 | -12,856 | Sold Out | 0 | $0.00 |
| Q4 2020 | -20,408 | Reduce 61.35% | 12,856 | $212.59 |
| Q3 2020 | +32,153 | Add 2894.06% | 33,264 | $171.42 |
| Q2 2020 | -3,049 | Reduce 73.29% | 1,111 | $191.72 |
| Q1 2020 | +4,160 | New Buy | 4,160 | $147.36 |
| Q4 2019 | -4,459 | Sold Out | 0 | $0.00 |
| Q3 2019 | +4,459 | New Buy | 4,459 | $135.01 |
| Q2 2019 | -5,801 | Sold Out | 0 | $0.00 |
| Q1 2019 | -55,711 | Reduce 90.57% | 5,801 | $103.95 |
| Q4 2018 | -114,490 | Reduce 65.05% | 61,512 | $113.86 |
| Q3 2018 | +101,291 | Add 135.58% | 176,002 | $115.34 |
| Q2 2018 | +74,711 | New Buy | 74,711 | $103.59 |
| Q1 2018 | -4,751 | Sold Out | 0 | $0.00 |
| Q4 2017 | +4,751 | New Buy | 4,751 | $84.61 |
| Q2 2017 | -9,715 | Sold Out | 0 | $0.00 |
| Q1 2017 | -3,218 | Reduce 24.88% | 9,715 | $71.95 |
| Q4 2016 | -283,450 | Reduce 95.64% | 12,933 | $62.01 |
| Q3 2016 | +33,425 | Add 12.71% | 296,383 | $64.79 |
| Q2 2016 | +150,509 | Add 133.85% | 262,958 | $63.23 |
| Q1 2016 | +112,449 | New Buy | 112,449 | $57.82 |
| Q4 2015 | -4,210 | Sold Out | 0 | $0.00 |
| Q3 2015 | +4,210 | New Buy | 4,210 | $51.07 |
| Q3 2014 | -18,321 | Sold Out | 0 | $0.00 |
| Q2 2014 | -511,695 | Reduce 96.54% | 18,321 | $50.65 |
| Q1 2014 | +295,129 | Add 125.65% | 530,016 | $44.69 |
| Q4 2013 | +209,695 | Add 832.39% | 234,887 | $47.08 |
| Q3 2013 | -31,125 | Reduce 55.27% | 25,192 | $52.83 |
| Q2 2013 | +56,317 | Add 0.00% | 56,317 | $45.14 |
Joel Greenblatt's ResMed Investment FAQs
Joel Greenblatt first purchased ResMed Inc. (RMD) in Q2 2013, acquiring 56,317 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held ResMed Inc. (RMD) for 45 quarters since Q2 2013.
Joel Greenblatt's largest addition to ResMed Inc. (RMD) was in Q1 2014, adding 530,016 shares worth $23.69 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 86,133 shares of ResMed Inc. (RMD), valued at approximately $20.75 M.
As of the Q4 2025 filing, ResMed Inc. (RMD) represents approximately 0.08% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in ResMed Inc. (RMD) was 530,016 shares, as reported at the end of Q1 2014.